article thumbnail

TuSimple Prices IPO, Starts Trading Today

socalTECH

San Diego-based TuSimple priced its IPO last night, saying that it will sell 33,783,783 shares of its Class A common stock at the price of $40.00 per share, raising just over $1 billion for the company. The company will begin trading this morning on the Nasdaq Global Select Market as TSP.

Pricing 113
article thumbnail

VelosBio Finds $137M For Oncology Efforts

socalTECH

San Diego-based biopharmaceuticals developer VelosBio says it has raised $137M in a Series B funding roudn, to go towards its oncology efforts. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, Wellington Management Company, as well as the company's existing investors.

San Diego 113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

TakeLessons Rolls Out New Service, TakeLessons Live

socalTECH

San Diego-based TakeLessons , which operates an online marketplaceto connect users with instructors in such areas as singing, piano, guitar, Spanish, and other areas, said this week that it has launched a new service called TakeLessons Live. The new service provides unlimited, live online group classes, via a monthly subscription.

Services 100
article thumbnail

Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019

Xconomy

Gossamer Bio, the San Diego-based biotech founded by former Receptos executives, has raised $276 million in its initial public offering, a total that puts it in a rare class among biotechs that have gone public in recent years. The amount raised surpassed expectations.

article thumbnail

Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive’s End

Xconomy

Two new battlegrounds emerged this week in the nation’s ongoing drug pricing debate. The first involved television: The federal government hopes that blaring prices in TV ads will essentially pressure drug makers into lowering them, and the pharma lobby fired back. Read more » Reprints | Share:

Pricing 74
article thumbnail

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

Xconomy

If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. But the first mover isn’t infallible if someone else has something better. That’s something the The Medicines Co. is counting on.

Pricing 84
article thumbnail

Zynga IPO Rewards SoCal Investors

socalTECH

Among the biggest winners of the IPO of Zynga is San Diego-based Avalon Ventures , which owned 32,169,401 shares of Zynga before the IPO, a stake which was worth $321M based on Zynga's opening price this morning. Zynga priced at $10.00 Zynga looks to be among the most visible exits from that firm's portfolio yet.